【招银国际】Yanlord：Resilient FY22 results and business model; maintain Buy.pdf

FY22预计稳中向好，疫情无碍新财年起航，品牌韧性历经考验

FY22E preview; Bumpy recovery in 2023

华润医药：1H22业绩巩固了FY22E的正面

石四药集团：强劲的1H22结果；但FY22E指引略低

FY22 net margins better than expected

IMAX China(01970)FY22业绩会纪要-港股20230223-调研纪要

Resilient FY22／1H23 despite industry headwinds

Outperforming FY22E, promising FY23E and not-far-fetching FY25E target

遥望科技(002291)FY22&1Q23业绩交流会-调研纪要

FY22 largely in-line; Gradual recovery on track